Oncotarget

Research Papers:

BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells

Yoshiko Shimizu, Nicole Mullins, Zannel Blanchard and Wael M. ElShamy _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2012; 3:299-313. https://doi.org/10.18632/oncotarget.462

Metrics: PDF 1850 views  |   HTML 2626 views  |   ?  


Abstract

Yoshiko Shimizu, Nicole Mullins, Zannel Blanchard and Wael M. ElShamy

1 Cancer Institute and Department of Biochemistry, University of Mississippi Medical Center, Jackson, MS

Received: February 29, 2012; Accepted: March 15, 2012; Published: March 19, 2012;

Keywords: BRCA1/p220, BRCA1-IRIS, breast cancer, RNA stability, survival, invasion/metastasis

Correspondence:

Wael M. ElShamy,

Abstract

BRCA1/p220-assocaited and triple negative/basal-like (TN/BL) tumors are aggressive and incurable breast cancer diseases that share among other features the no/low BRCA1/p220 expression. Here we show that BRCA1/p220 silencing in normal human mammary epithelial (HME) cells reduces expression of two RNA-destabilizing proteins, namely AUF1 and pCBP2, both proteins bind and destabilize BRCA1-IRIS mRNA. BRCA1-IRIS overexpression in HME cells triggers expression of several TN/BL markers, e.g., cytokeratins 5 and 17, p-cadherin, EGFR and cyclin E as well as expression and activation of the pro-survival proteins; AKT and survivin. BRCA1-IRIS silencing in the TN/BL cell line, SUM149 or restoration of BRCA1/p220 expression in the mutant cell line, HCC1937 reduced expression of TN/BL markers, AKT and survivin and induced cell death. Collectively, we propose that BRCA1/p220 loss of expression or function triggers BRCA1-IRIS overexpression through a post-transcriptional mechanism, which in turn promotes formation of aggressive and invasive breast tumors by inducing expression of TN/BL and survival proteins.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 462